Antibodies
8 January 2025
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors7 January 2025
New drug application for core product trastuzumab botidotin accepted by the National Medical Products Administration7 January 2025
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager7 January 2025
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program7 January 2025
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody3 January 2025
Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX0442 January 2025
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate31 December 2024
Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene30 December 2024
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)30 December 2024
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging27 December 2024
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with ChemotherapyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports